Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study.

Détails

ID Serval
serval:BIB_BF11F7A7D705
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study.
Périodique
Klinische Pädiatrie
Auteur⸱e⸱s
Baenziger O., Waldvogel K., Ghelfi D., Arbenz U., Fanconi S.
ISSN
0300-8630
Statut éditorial
Publié
Date de publication
1999
Peer-reviewed
Oui
Volume
211
Numéro
6
Pages
438-41
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Randomized Controlled Trial - Publication Status: ppublish
Résumé
BACKGROUND: Indomethacin therapy for closure of a patent ductus arteriosus in preterm neonates is responsible for transient renal insufficiency. Dopamine theoretically reduces the renal side effects of indomethacin therapy. PATIENTS: 33 neonates with a mean gestational age of 28.5 weeks who received indomethacin for treatment of a symptomatic PDA were included in a prospective randomized controlled clinical study. METHOD: 15 patients were treated with indomethacin alone (control group), 18 patients with indomethacin and dopamine (study group). Indomethacin was given in a dose of 0.2 mg/kg/dose intravenously, all patients received three doses with intervall of 12 hours. The dose of dopamine was in all patients 4 micrograms/kg per minute commencing 2 hours prior to the first dose of indomethacin and continuing for 12 hours after the third dose. RESULTS: Indomethacin induced a significant increase in serum creatinin (76.3 mumol/l vs 99.7 mumol/l for the control group, and 70.7 mumol/l vs 93.0 mumol/l for the study group), and weight (1259 g vs 1316 g for the control group, and 1187 g vs 1221 g for the study group). The increase systolic blood pressure (61 mmHg vs 65.7 mmHg) in the study group was significant (p < 0.05) but remained unchanged in the control group. The changes between the study group and the control group were not significant either in serum creatinin, fractional excretion of sodium, or weight gain. The failure rate of ductal closure was not different between the two groups. CONCLUSION: The additional use of dopamine does not reduce the renal side effects of indomethacin.
Mots-clé
Cardiotonic Agents, Cardiovascular Agents, Creatinine, Dopamine, Dose-Response Relationship, Drug, Ductus Arteriosus, Patent, Female, Humans, Indomethacin, Infant, Newborn, Kidney Failure, Male, Natriuresis, Prospective Studies, Statistics, Nonparametric, Treatment Outcome, Weight Gain
Pubmed
Web of science
Création de la notice
25/01/2008 11:06
Dernière modification de la notice
20/08/2019 16:33
Données d'usage